High-dose ruthenium-106 plaque therapy for circumscribed choroidal hemangioma: a retrospective study of 25 Chinese patients

• 作者: En-Zhong Jin Jian-Hong Liang Jing Li
• 来源期刊: 国际眼科杂志:英文版
• 学科: 医学
• 关键词: circumscribed choroidal HEMANGIOMA RADIOTHERAPY ruthenium-106 Chinese patients RETROSPECTIVE study
• 年，卷（期）: 2020,（3）
• 页码范围: 425-430
• 页数: 6页
• 分类号: R739.7

摘要

AIM:To evaluate the efficacy and safety of ruthenium-106(106Ru)plaque radiotherapy at a dose(>50 Gy)higher than recommended(29-50 Gy)for treatment of circumscribed choroidal hemangioma(CCH)in Chinese patients.METHODS:This retrospective study included 25symptomatic CCH patients undergoing 106Ru plaque brachytherapy involving 25 eyes between January 2005and August 2016.Ophthalmic examination was performed at the baseline and at each post-treatment follow-up visit,using best-corrected visual acuity(BCVA),dilated fundus examination,and B-scan ultrasonography.The primary efficacy outcome measures included the changes in BCVA and hemangioma dimensions at the last followup visit from the baseline.RESULTS:The mean follow-up duration was 28.0±26.6(range,12-110)mo.All the hemangiomas were located in the posterior pole except for two involving the fovea.The mean apex dose of 106Ru plaque radiotherapy was84.4±19.7 Gy.The mean BCVA improved from 41.4±29.3(0-97)at the baseline to 53.0±33.8(0-97)ETDRS letters at the last visit(P=0.01).The mean hemangioma height declined from 3.98±0.88(2.40-5.50)mm to 0.84±1.63(0-6.47)mm(P≤0.001),and the greatest linear diameter(GLD)reduced from 9.36±2.23(6.80-15.00)to 7.40±2.45(0-13.00)mm(P≤0.001).Hemangioma size increased in one(4%)eye with a worsened vision,and subretinal fluid completely resolved in all but one patient(4%).Radiationrelated retinopathy was observed in two patients at posttreatment 9 and 11mo,respectively.CONCLUSION:106Ru plaque brachytherapy at a dose(>50 Gy)higher than recommended(29-50 Gy)is an effective treatment regimen for symptomatic CCH associated with significantly improved visual acuity and a favorable safety profile in Chinese patients.